Trial Profile
A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase [HSV thymidine kinase gene therapy] for the Treatment of Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ganciclovir (Primary) ; HSV thymidine kinase gene therapy (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2005 New trial record.